Patents
Literature
7 results about "Thrombogenicity" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Thrombogenicity refers to the tendency of a material in contact with the blood to produce a thrombus, or clot. It not only refers to fixed thrombi but also to emboli, thrombi which have become detached and travel through the bloodstream. Thrombogenicity can also encompass events such as the activation of immune pathways and the complement system. All materials are considered to be thrombogenic with the exception of the normal state of endothelial cells which line blood vessels. Certain medical implants appear non-thrombogenic due to high flow rates of blood past the implant, but in reality all are thrombogenic to a degree. Various surface treatments are available to minimize these thrombogenic effects.
ANTIMMICROBIAL, NON-THROMBOGENIC POLYMER COMPOSITIONS
Owner:LUBRIZOL ADVANCED MATERIALS INC
Inhibiting platelet absorption
The present disclosure relates to inhibition of platelet absorption. Cardiovascular grafts with highly reduced thrombosis are provided. The cardiovascular graft is an electrospun nonwoven web produced from a supramolecular polymer of large diameter fibers. The cardiovascular graft can be implanted in a human body as a vascular graft to allow blood vessel bypass / reconstruction, or repeated venous access for dialysis treatment, as well as other small diameter vascular disorders.
Owner:XELTIS
End-group zwitterionic polyurethane surface modifying additive
PCT designated stageWO2026099109A1Antithrombogenic treatmentPolyurea/polyurethane coatingsPolymer scienceThrombogenicity
A zwitterionic polyurethane additive, a base polymer comprising zwitterionic polyurethane additive, a medical device comprising an admixture of a base polymer and zwitterionic polyurethane additive, a method of reducing a thrombogenic and / or bacterial adhesion property of an admixture of a base polymer and zwitterionic polyurethane additive, are disclosed. The zwitterionic polyurethane additive is a reaction product of an isocyanate group terminated polyurethane prepolymer with tertiary amine alcohols, followed by reaction with at least one heterocycle selected from the group consisting of a sultone, a lactone, or a 2-alkoxy-2-oxo-1,3,2-dioxaphospholane.
Owner:EVONIK OPERATIONS GMBH
Compositions comprising GPCR-based chimeric antigen receptors and methods of use
PendingCN121909209APolypeptide with localisation/targeting motifAntibody mimetics/scaffoldsThrombogenicityAntigen receptors
The present invention relates to chimeric aGPCR and uses thereof. By redirecting the intracellular signal response to the desired target, the chimeric aGPCR may be used in a manner similar to a chimeric antigen receptor. The chimeric aGPCR may also bind to platelets or engineered non-thrombogenic platelets for targeted drug delivery.
Owner:XAP THERAPEUTICS LTD
Non-thrombogenic devices for treating edema
The invention provides intravascular devices for treating certain medical conditions such as edema without causing thrombosis. The intravascular devices of the disclosure include non-thrombogenic surfaces that improve blood compatibility by reducing device-related thrombus formation and inflammatory reactions. The non-thrombogenic surfaces may include surface topographies (e.g., surface roughness) and modified chemistries (e.g., coatings and / or treatments), which prevent thrombosis by reducing local shear forces and inhibiting adhesion of blood clotting factors.
Owner:WHITE SWELL MEDICAL LTD
Ceramic barrier for reducing metal ion elution from metal-based coronary stents and a method of manufacturing the same
The present invention relates to metal-based coronary stents designed to reduce or eliminate the release of metal ions into the physiological environment. The invention further provides a method of manufacturing such stents, wherein a metal alloy tube is laser-cut to form a stent platform comprising longitudinal and circumferential struts, followed by cleaning, electropolishing, heat-treatment, passivation and ultrasonic ethanol cleaning. The processed platform is coated with a ceramic layer of titanium nitride having a uniform thickness in the range of 200-3000 nm using physical vapor deposition. The titanium nitride coating acts as a biocompatible ion-barrier, improving hemocompatibility and reducing complications such as restenosis, inflammation, thrombogenicity, and long-term metal ion elution, while maintaining mechanical integrity and radial strength required for vascular deployment.
Owner:SREE CHITRA TIRUNAL INST FOR MEDICAL SCI & TECH
Non-thrombogenic devices for treating edema
The invention provides intravascular devices for treating certain medical conditions such as edema without causing thrombosis. The intravascular devices of the disclosure include non-thrombogenic surfaces that improve blood compatibility by reducing device-related thrombus formation and inflammatory reactions. The non-thrombogenic surfaces may include surface topographies (e.g., surface roughness) and modified chemistries (e.g., coatings and / or treatments), which prevent thrombosis by reducing local shear forces and inhibiting adhesion of blood clotting factors.
Owner:WHITE SWELL MEDICAL LTD